9.70
price down icon2.32%   -0.23
after-market 시간 외 거래: 9.96 0.26 +2.68%
loading
전일 마감가:
$9.93
열려 있는:
$9.69
하루 거래량:
1.16M
Relative Volume:
0.54
시가총액:
$634.88M
수익:
$27.10M
순이익/손실:
$-24.31M
주가수익비율:
-11.69
EPS:
-0.83
순현금흐름:
$-33.33M
1주 성능:
+4.86%
1개월 성능:
-1.92%
6개월 성능:
-29.71%
1년 성능:
+100.41%
1일 변동 폭
Value
$9.47
$10.02
1주일 범위
Value
$8.91
$11.58
52주 변동 폭
Value
$3.52
$23.40

Capricor Therapeutics Inc Stock (CAPR) Company Profile

Name
명칭
Capricor Therapeutics Inc
Name
전화
(310) 358-3200
Name
주소
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Name
직원
160
Name
트위터
@Capricor
Name
다음 수익 날짜
2025-03-19
Name
최신 SEC 제출 서류
Name
CAPR's Discussions on Twitter

CAPR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
CAPR
Capricor Therapeutics Inc
9.70 634.88M 27.10M -24.31M -33.33M -0.83
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-20 개시 Roth Capital Buy
2024-10-21 개시 Piper Sandler Overweight
2024-05-17 개시 Oppenheimer Outperform
2024-01-05 개시 Cantor Fitzgerald Overweight
2022-10-26 개시 Ladenburg Thalmann Buy
2018-12-26 다운그레이드 Maxim Group Buy → Hold
2018-01-26 재확인 H.C. Wainwright Buy
2017-09-15 재확인 H.C. Wainwright Buy
2017-02-13 재개 Rodman & Renshaw Buy
2016-07-06 재개 H.C. Wainwright Buy
2016-06-15 개시 ROTH Capital Buy
모두보기

Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스

pulisher
Jun 18, 2025

US FDA’s Top Cell and Gene Therapy Regulators Forced Out - insights.citeline.com

Jun 18, 2025
pulisher
Jun 18, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor - Bluefield Daily Telegraph

Jun 18, 2025
pulisher
Jun 18, 2025

Capricor gets FDA's Orphan Drug status for muscle disorder therapy - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

Capricor Therapeutics Announces Orphan Drug Designation for - GlobeNewswire

Jun 18, 2025
pulisher
Jun 17, 2025

Capricor Therapeutics (CAPR) Rating Reiterated by Roth Capital | CAPR Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Capricor Therapeutics (CAPR) Gains FDA Orphan Drug Status for Deramiocel - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire

Jun 17, 2025
pulisher
Jun 17, 2025

Capricor Therapeutics' Deramiocel Wins FDA Orphan Drug Designation for Becker Muscular Dystrophy - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Capricor Therapeutics (CAPR) Receives Orphan Drug Designation for BMD Treatment | CAPR Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Capricor Scores Double Win: FDA Orphan Drug Status for Becker MD Plus DMD Approval Progress - Stock Titan

Jun 17, 2025
pulisher
Jun 15, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor ... - Eagle-Tribune

Jun 15, 2025
pulisher
Jun 14, 2025

FDA Grants Orphan Status to Capricor's Becker Muscular Dystrophy Treatment (CAPR) | CAPR Stock News - GuruFocus

Jun 14, 2025
pulisher
Jun 14, 2025

Capricor Therapeutics (CAPR) Shares Dip Seen as Buying Opportuni - GuruFocus

Jun 14, 2025
pulisher
Jun 14, 2025

Capricor Therapeutics (CAPR) Sees Unusual Put Activity | CAPR St - GuruFocus

Jun 14, 2025
pulisher
Jun 13, 2025

Capricor (CAPR) Shares Decline Amid FDA Advisory Panel Developments | CAPR Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Capricor Therapeutics (CAPR) Receives Buy Rating from HC Wainwri - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Capricor Therapeutics (CAPR) Receives Buy Rating from HC Wainwright & Co. | CAPR Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Capricor Therapeutics (CAPR) Shares Drop After FDA Withdraws Mee - GuruFocus

Jun 13, 2025
pulisher
Jun 12, 2025

Capricor gets Form 483 from FDA; WuXi Biologics’ new China factory - Endpoints News

Jun 12, 2025
pulisher
Jun 12, 2025

Capricor says FDA inspection brought Form 483 with several observations - Yahoo Finance

Jun 12, 2025
pulisher
Jun 11, 2025

Capricor Therapeutics (CAPR) Manufacturing Facility Cleared by F - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Capricor Therapeutics (CAPR) Shares Decline Amid FDA Inspection Report - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Capricor Therapeutics (CAPR) Advances Deramiocel Approval Proces - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Capricor: A Hold Rating With Regulatory FDA Form Given For Deramiocel Advancement (CAPR) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Capricor Therapeutics Announces Key Regulatory Updates for its D - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’ - Asianet Newsable

Jun 11, 2025
pulisher
Jun 11, 2025

Capricor Therapeutics (CAPR) Manufacturing Facility Cleared by FDA | CAPR Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Capricor Therapeutics' Duchenne Therapy Facility Inspection Completed by FDA - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

Capricor falls after facility inspection related to deramiocel - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Capricor Therapeutics stock falls after FDA inspection of manufacturing facility - Investing.com Australia

Jun 11, 2025
pulisher
Jun 11, 2025

Capricor Therapeutics stock falls after FDA inspection of manufacturing facility By Investing.com - Investing.com Nigeria

Jun 11, 2025
pulisher
Jun 11, 2025

Capricor’s DMD therapy clears FDA pre-license inspection By Investing.com - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program - GlobeNewswire

Jun 11, 2025
pulisher
Jun 11, 2025

Capricor's DMD Drug Hits 3 Major FDA Milestones: Advisory Committee Set for July 30 - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Estimates CAPR FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Behind the Scenes of Capricor Therapeutics's Latest Options Trends - Benzinga

Jun 10, 2025
pulisher
Jun 09, 2025

(CAPR) Trading Signals - news.stocktradersdaily.com

Jun 09, 2025
pulisher
Jun 08, 2025

Wellington Management Group LLP Purchases New Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Capricor Therapeutics Sees Unusually High Options Volume (NASDAQ:CAPR) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc.CAPR - FinancialContent

Jun 06, 2025
pulisher
Jun 05, 2025

Capricor Therapeutics (CAPR) Sees Borrow Rate Surge | CAPR Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 04, 2025

Millennium Management LLC Acquires 12,285 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

BNP Paribas Financial Markets Reduces Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 03, 2025

Two Sigma Investments LP Has $1.64 Million Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Bank of America Corp DE Purchases 154,127 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Jun 02, 2025
pulisher
Jun 01, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Connect - ACCESS Newswire

Jun 01, 2025
pulisher
May 31, 2025

Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World

May 31, 2025
pulisher
May 31, 2025

Deutsche Bank AG Takes Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World

May 31, 2025
pulisher
May 30, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Reach Out - ACCESS Newswire

May 30, 2025

Capricor Therapeutics Inc (CAPR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Capricor Therapeutics Inc 주식 (CAPR) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Bergmann Anthony
CHIEF FINANCIAL OFFICER
Mar 03 '25
Option Exercise
1.39
2,500
3,475
8,223
Litvack Frank
Director
Mar 03 '25
Option Exercise
1.39
25,000
34,750
132,382
DUNBAR GEORGE W JR
Director
Mar 03 '25
Option Exercise
1.39
750
1,042
11,306
COLLIER EARL M JR
Director
Feb 27 '25
Option Exercise
1.39
750
1,042
57,606
Krasney Karen
EVP, GENERAL COUNSEL
Dec 13 '24
Option Exercise
1.39
8,000
11,120
28,047
Litvack Frank
Director
Dec 03 '24
Option Exercise
1.10
20,391
22,430
46,278
Nippon Shinyaku Co Ltd
10% Owner
Sep 20 '24
Buy
5.36
2,798,507
14,999,998
7,090,351
Musket David B
Director
Aug 07 '24
Option Exercise
1.39
34,000
47,260
81,692
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
자본화:     |  볼륨(24시간):